# TEM — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-23. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 5 · Fundamentals 4 · Technicals 3.5 · Growth 8 · Risk 8.5

## Summary

Tempus AI is a hyper-growth, deeply unprofitable precision-medicine platform trading at $46.96, down 55% from 52-week highs and 20% YTD, with a binary Q2 earnings print in 7 days. The $1.5B all-stock Personalis acquisition adds MRD capability but introduces dilution risk into a 31.67% short float, and the model's own 1d/1wk forecasts have been beaten by the naive baseline — I'd stand aside as HOLD ahead of July 30.

## Price targets (3-month horizon)

- Bear: $38.00
- Base: $48.00
- Bull: $58.00

## News context

The dominant catalyst is the July 20 announcement of a $1.5B all-stock acquisition of Personalis (PSNL), which brings a Medicare-reimbursed MRD (minimal residual disease) test in-house after three years of reselling it. Signal: this vertically integrates a strategic asset in cancer monitoring and eliminates a revenue-share drag, but it comes at a premium and via dilution rather than cash — negative near-term for share supply/demand given the 31.67% short float. Secondary: the OneOme pharmacogenomics launch is a modest incremental revenue lever, not a needle-mover. Coverage from Simply Wall St. flags integration risk and questions whether the bull case is priced in. Noise: TV crawl airtime (121x in 3d, avg 6.89% moves) reflects volatility but not narrative. Retail sentiment is mildly bullish and focused on the Personalis deal mechanics and short positioning — treat as noise, not fact.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/tem-ai-stock-forecast-a7d6c982571ada95928c6b2e6aca2d58
- AI-generated; model outputs can be wrong. Not financial advice.